David Jansen Email & Phone Number

Johannesburg Area, South Africa

Auckland Park Kingsway Campus, Johannesburg, South Africa

Pelindaba, South Africa

Assist Necsa's NTeMBI programme in the growth strategy that is envisaged for radiopharmaceutical drug development by attracting more funding from the Department of Science and Technology (DST) and capitalizing on funding opportunities such as the South African Research Infrastructure Roadmap (SARIR). Functions include: business plan development for NTeMBI (moving further down the value chain); NTeMBI reports to DST; development of future plan of the SA Research Infrastructure Roadmap for Nuclear Medicine; stakeholder management when moving NTeMBI into new territory; radiolabeling lab support to visiting (and resident) NTeMBI students to Necsa.

Fourways, Johannesburg, South Afria

David's primary function within Solar Implement is to oversee all the aspects at the heart of the organization. This includes being the management interface with banks, SARS, CIPC, accountants, procurement and sales. He serves alongside the senior directors of the organization - coordinating functions of the technical and finance directors, and facilitates decision making on daily basis.

Fourways, Johannesburg

As an assistant to the managing director of Wind Implement, David handles the regulatory and I.T. related activities. His responsibilities encompasses monitoring of NERSA and DOE regulations to ensure grid code compliance, and Small-Scale Embedded Generation (SSEG). A component of this work is the facilitation of collaborative studies with local and international research institutions for wind turbine micro-grid integration with the national utility. Additional tasks include web and database administration, and other administrative aspects that involves Independent Power Producer (IPP) projects, and to a limited extent, interaction with tax and corporate consultants.

South Africa

During his 11 years as a scientist at Necsa, David has been actively involved in a number of bilateral co-operations for the transfer of technology between South Africa and various participating countries. He visited the Flerov labs at the Joint Institute for Nuclear Research (JINR) in Dubna, Russia, where he received training on various nuclear and radiochemical techniques for radioisotope production. He also represented Necsa in a scientific exchange program with the Centre of Isotopes (CENTIS) in Havana, Cuba. David participated in, and presented at various international conferences in Europe, Asia, North America and South Africa.

David was employed as a senior scientist at the South African Nuclear Energy Corporation (SOC) Ltd where the focus of his research was the development of radioisotopes and radiopharmaceuticals, as well as researching novel ways of improving on existing methods and technologies. These included the radiolabeling and evaluation of biologically active molecules and other tumour-specific molecules/vectors for diagnostic and therapeutic use; e.g. monoclonal antibodies for radioimmunotherapy, and bishposphonates for palliation of painful bone metastases. The core of his responsibilities included the establishment of technologies at Necsa that aim at addressing key/significant diseases such as cancer, particularly focusing on the application of novel radiotherapeutics and/or the incorporation of therapies already introduced in the developed or first-world countries. In so doing, David coordinated and facilitated research with local and international collaborators at Necsa, towards achieving the transfer of relevant technologies. An example of this being the scientific exchange visits between the Centre of Isotopes (CENTIS) in Havana, Cuba and Necsa during 2012/2013 where expertise in the radiolabeling of monoclonal antibodies were shared. The uniqueness of such technologies in the field of nuclear and radiochemistry also presents new avenues for development in South Africa. David was also actively involved in the execution of clinical trials, where he shared the role of responsible person/pharmacist within the Department of Radiochemistry for the dispensing and release of patient doses to the hospital. Recent studies include that of Pt-195 radiolabeled Cisplatin, cis[Pt-195]PtCl2(NH3)2; and 2-fluoroethylcholine radiolabeled with F-18.

Doctor Of Philosophy (Ph.D.), Radiochemistry

Master Of Business Administration (M.B.A.), Global Mba

Master'S Degree, Chemistry

Activities and Societies: Fencing

Bsc(Hons), Chemistry

Bsc, Chemistry